Freshfields Bruckhaus Deringer (‘Freshfields’) has provided Hong Kong law advice to HUTCHMED (China) Limited (‘Hutchmed’) on the global offering and triple primary listing of 104 million of its shares (before any exercise of the Over-allotment Option) on the Hong Kong Stock Exchange (‘HKSE’). The transaction raised proceeds of approximately HK$4.1bn (before any exercise of the Over-allotment Option). Trading in the shares commenced today (30 June 2021).

Hutchmed is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. The company started operations in 2000 as a wholly owned subsidiary of CK Hutchison. Its shares have been traded on the AIM market of the London Stock Exchange since 2006, and its American Depositary Shares have been listed on Nasdaq since 2016.

The Freshfields team advising on the transaction was led by partner Grace Huang.